AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01894165
Drug: ALXN1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
Trial: NCT01894165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
Trial: NCT04248452
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04248452
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04248452
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04248452
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01107496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules administered orally 3 times a day
Trial: NCT00392288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDI over twelve weeks
Trial: NCT00745875
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg oral tablet, once daily
Trial: NCT00745875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg oral tablet, once daily
Trial: NCT04576455
Drug: LHRH Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.
Trial: NCT02930551
Drug: Isotonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02935036
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical product
Trial: NCT02771158
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be administered to double blind the study
Trial: NCT03345550
Drug: Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules.
Trial: NCT03345550
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA \& 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
Trial: NCT00181246
Drug: Transdermal Fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01251055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starch
Trial: NCT02132260
Drug: Naftin® (Naftifine Hydrochloride) Cream 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
Trial: NCT02132260
Drug: Placebo Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
Trial: NCT04691115
Drug: AM1476
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM1476 Capsules
Trial: NCT04691115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsules
Trial: NCT06638749
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of normal saline
Trial: NCT00936650
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
Trial: NCT03653546
Drug: AZD3759
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3759 200mg PO BID.
Trial: NCT00835549
Drug: OMNICEF® for oral suspension 250 mg/5mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 250 mg/5mL, single-dose non-fasting
Trial: NCT00835042
Drug: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 15/25 mg
Trial: NCT00835042
Drug: UNIRETIC® 15/25 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 15/25 mg
Trial: NCT02592863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take placebo 3 times per day for 12 weeks
Trial: NCT03228732
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
Trial: NCT03228732
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
Trial: NCT03228732
Drug: Fluoxetine and DHEA
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
Trial: NCT03453541
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 % Normal saline 1ml/60kg up to a maximum dose of 1ml IV bolus (an equivalent volume as per kg Ketorolac Trimethamine dose) at the completion of the tonsillectomy in the operating room.
Trial: NCT01602913
Drug: Pravastatin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
Trial: NCT01602913
Drug: Pravastatin and paroxetine combined
RxNorm normalized name: pravastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
Trial: NCT00803855
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, single dose
Trial: NCT03890094
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
Trial: NCT01787747
Drug: AVP-786 Dose 1/Q Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01787747
Drug: AVP-786 Dose 1/Q Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01787747
Drug: AVP-786 Dose 2/Q Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00581919
Drug: Bort, Dex, and Dox with ALCAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
Trial: NCT02800785
Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
Trial: NCT00200746
Drug: Arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amino Acid Arginine
Trial: NCT01344655
Drug: Atimos®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 μg pMDI
Trial: NCT01344655
Drug: Serevent™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 25 µg pMDI
Trial: NCT01344655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00854737
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT01933763
Drug: REGN1193
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01706315
Drug: GSK2140944
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
Trial: NCT01706315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be available
Trial: NCT02621944
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
Trial: NCT00437073
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
Trial: NCT02810392
Drug: Intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery is with the Vianase device, 0.5 cc of normal saline
Trial: NCT00299013
Drug: COLAL-PRED®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
Trial: NCT00299013
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
Trial: NCT04412746
Drug: MANAGEMENT OF COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MANAGEMENT OF COVID-19 Oxygen therapy to maintain SpO2 target more than 94%. Low molecular weight heparin (LMWH) at preventive doses. Empirical antibiotic treatment.~Specific treatment for COVID-19 (approved by Algerian Ministry of Health) First line: Hydroxychloroquin: 200 mg oral three times a day for 10 days, with association of Azithromycin 250 mg oral : 500 mg the first day and 250 mg once a day for 4 days. Sulfate de Zinc : 220 mg once a day for 5 days. Second line: Lopinavir/ritonavir capsule 200 mg/50 mg, oral 2 capsules each times, twice a day during 5 to 7 days.~IF AGGRAVATION OR CRITICAL ILL CONDITION AT PRESENTATION Increase oxygenation flow. Consider Glucocorticoids. 3. Consider the diagnosis of pulmonary embolism and treat with LMWH at therapeutic doses.~MANAGEMENT OF DIABETES Discontinue metformin. Start or adjust insulin doses according to personalized glycemic target of patient.
Trial: NCT04584008
Drug: FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.
Trial: NCT04584008
Drug: Other Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..
Trial: NCT00362115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets, orally, once daily for up to 8 weeks.
Trial: NCT04665895
Drug: FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily inhalation throughout the study
Trial: NCT04665895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily inhalation throughout the study
Trial: NCT03682484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00553969
Drug: placebo and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule once daily for 9 months; dosage unknown
Trial: NCT00835354
Drug: CEFZIL® for Oral Suspension 250 mg/5mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 250 mg/5 mL, single-dose fasting
Trial: NCT03510715
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Trial: NCT03510715
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule,~Route of administration: oral
Trial: NCT03510715
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Trial: NCT03510715
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Trial: NCT03510715
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: tablet,~Route of administration: oral
Trial: NCT01092650
Drug: Deuterated phenanthrene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deuterated phenanthrene 10 micrograms
Trial: NCT03997500
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a bolus of normal saline was given followed by normal saline infusion
Trial: NCT03997500
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a bolus of norepinephrine was given followed by norepinephrine infusion
Trial: NCT02757768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
Trial: NCT02429895
Drug: ABT-122
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT01128595
Drug: FF/GW642444M
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01128595
Drug: GW642444M
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01128595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01532648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
Trial: NCT01857232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator
Trial: NCT01857232
Drug: APD403 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride IV 20 mg
Trial: NCT01857232
Drug: APD403 oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride oral 10, 20 or 40 mg
Trial: NCT02929420
Drug: Xiaoru Sanjie capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
Trial: NCT00775671
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
Trial: NCT02723669
Drug: AR10
RxNorm normalized name: ADHESIVE DISC,DBL-FACED 1.5IN MAR107-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effervescent tablet
Trial: NCT02730169
Drug: BGS649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules were taken weekly for a maximum of 24 weeks
Trial: NCT02730169
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules were taken weekly for a maximum of 24 weeks
Trial: NCT01147029
Drug: angiogenesis inhibitor GSAO
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00432107
Drug: APO866
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
Trial: NCT02371889
Drug: Inactive Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
Trial: NCT04883203
Drug: Vit-D 0.2 MG/ML Oral Solution [Calcidol]
RxNorm normalized name: vit-D 0.2 MG/ML Oral Solution [Calcidol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARM 1 : Cholecalciferol 200,000 IU / 1 mL .
Trial: NCT04883203
Drug: Physiological Irrigating Solution
RxNorm normalized name: physiological irrigating solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARM 2 : placebo
Trial: NCT01644331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
Trial: NCT05058443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo subcutaneously every 6 months (Q6M)
Trial: NCT03814291
Drug: IBI302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05mg/eye;Intraocular injection
Trial: NCT01661595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 capsule per day for four weeks.
Trial: NCT04414943
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For women in this group, placebo (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
Trial: NCT03814291
Drug: IBI302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15mg/eye;Intraocular injection
Trial: NCT03814291
Drug: IBI302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg/eye;Intraocular injection
Trial: NCT03814291
Drug: IBI302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg/eye;Intraocular injection
Trial: NCT03814291
Drug: IBI302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg/eye;Intraocular injection
Trial: NCT03814291
Drug: IBI302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg/eye;Intraocular injection
Trial: NCT01756456
Drug: rhNGF 10 μg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
Trial: NCT01756456
Drug: rhNGF 20 μg/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
Trial: NCT01916629
Drug: Photocil for Psoriasis
RxNorm normalized name: MG 217 Psoriasis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photocil for Psoriasis
Trial: NCT03033784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an intranasal placebo to match the oxytocin doses.
Trial: NCT01235637
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively.
Trial: NCT00434941
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00459550
Drug: GSK933776
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg
Trial: NCT00459550
Drug: Placebo to match GSK933776
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
Trial: NCT00583154
Drug: BLI-801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1
Trial: NCT00583154
Drug: BLI-801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 2
Trial: NCT00583154
Drug: BLI-801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 3
Trial: NCT00583154
Drug: BLI-801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 4
Trial: NCT01630109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo capsule made to look like the metoclopramide capsule.
Trial: NCT04632862
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 A mg